t2-18c3
mAbexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01021072)
Timeline
Indications
Mechanism of action
- Interleukin-1 alphaINHIBITOR
IL1A inhibitor
Prevents binding of IL1A to interleukin-1 receptor type 1.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109654 ↗
- ChEMBLCHEMBL2109653 ↗
Also known as
- ca-18c3
- ca-18c3
- cv-18c3
- cv-18c3
- mabp1
- mabp1
- ra-18c3
- ra-18c3
- t2-18c3
- t2-18c3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03047317 | Phase 1 | Feb 15, 2017 | XBiotech, Inc. |
| NCT02643654 | Phase 2 | Dec 1, 2015 | Hellenic Institute for the Study of Sepsis, University of Athens |
| NCT01474798 | Phase 2 | Feb 1, 2012 | XBiotech, Inc. |
| NCT01384630 | Phase 2 | Sep 1, 2011 | University of Michigan, XBiotech, Inc. |
| NCT01427699 | Phase 2 | Jun 1, 2011 | XBiotech, Inc. |
| NCT01270945 | Phase 2 | Jun 1, 2011 | Methodist Cancer Center, Houston, Texas, XBiotech, Inc. |
| NCT01260545 | Phase 1 | Apr 1, 2011 | XBiotech, Inc. |
| NCT01021072 | Phase 1 | Mar 1, 2010 | XBiotech, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| XBiotech, Inc. | For profit | 7 | 7 | 2 | 2010 |
| Hellenic Institute for the Study of Sepsis | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Athens | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1